01603 327 053
Practitioners
Patients
- Genotyping
State-of-the-art genotyping services - Pharmacogenetics
Personalised approach to prescribing medications - Metagenomic Sequencing
Profiling of gut, oral and vaginal microbiome - Bloodborne Infection Screening
Detection of key blood-borne infections. - Contract Research
Tailored solutions support for the entire assay lifecycle
PGx FOR CARDIOLOGY
Personalised Cardiovascular Treatment
AttoDiagnostics’ Pharmacogenomics Testing helps cardiologists personalise treatment plans, reducing the risk of adverse reactions and improving patient outcomes.
- Covers key cardiovascular drugs, including anticoagulants, beta-blockers, and statins
- Identifies genetic factors influencing metabolism and drug response
- Reduces risk of adverse events, including bleeding and QT prolongation
- UK-based laboratory
Pharmacogenomics for Cardiovascular Diseases
The effective prescribing of cardiovascular medications has grown increasingly complex, influenced by genetic variability in drug response and the challenges of managing polypharmacy. Interactions between co-prescribed agents frequently alter metabolic pathways, impacting therapeutic efficacy and patient outcomes.
Our state-of-the-art PGx testing solution utilises Thermofisher and Illumina platforms, alongside a world-class Clinical Decision Support System (CDSS). This system leverages a comprehensive database of the latest research and guidelines from CPIC, PharmGKB, FDA, DPWG, and other leading organisations. By providing valuable insights into personalised and evidence-based treatment options, our approach enhances the efficacy and safety of cardiovascular treatments by considering your patients' genetic profiles. Explore the benefits below.
-
Personalised Medication Management
PGx testing helps identify the most suitable medications for your patients by analysing their genetic profile. This process minimises trial and error, leading to faster and more effective treatment outcomes. Additionally, it reduces the risk of adverse drug reactions, such as bleeding risks with anticoagulants, statin-induced myopathy, and drug-induced arrhythmias.
-
Enhanced Efficacy and Reduced ADRs
By selecting cardiovascular medications that are more likely to be effective taking into consideration an individual's genetic profile and other factors, PGx testing improves treatment outcomes and patient satisfaction. It allows you to understand genetic predispositions to adverse drug reactions such as bleeding, bruising, anaemia, fatigue, bradycardia, coughs and sexual dysfunction, to name a few.
-
Optimised Dosage
Genetic insights from PGx testing can guide dosage adjustments tailored to each patient’s unique metabolism, leading to administration of either a higher or lower dose. Finding the right dosage helps improve the overall effectiveness of the treatment while minimising the potential of any side effects.
What Our Pharmacogenomics Report Covers
Our pharmacogenomic (PGx) report is divided into two sections: a summary overview and a detailed analysis. The quick overview, shown below, highlights potential cardiovascular medication interactions at a glance, allowing you to easily identify any challenges associated with the prescribed treatment plan. The detailed report provides a gene-by-gene review of genetic variations and their likely impact on the metabolism and effectiveness of cardiovascular medications and therapies.
Pharmacogenomics Testing Panel
AttoDiagnostics runs genetic panels tailored for genetic markers relevant to cardiovascular medications response to optimise treatment for conditions such as hypertension, hyperlipidemia, arrhythmias, and heart failure.
Get a Business QuoteAntiarrhythmics
Antithrombotics
Beta Blockers
Cholesterol Lowering
How Pharmacogenomic Testing Works
Genetic testing for cardiovascular medications is a straightforward and non-invasive process. Your patient will provide a buccal swab sample, which can be collected conveniently at home or in a healthcare setting under the guidance of a trained sample collection professional. Once collected, the swab is returned to the AttoDiagnostics pharmacogenomic testing facility, where we analyse the sample in our laboratory to generate the PGx report.
Step 1
Sample Collection
Our preferred solution is to collect buccal swab samples or a blood sample from the patient, typically from the finger. For optimal results, two buccal swab samples are required, or five circles of dried blood on a blood spot card.
Step 2
Genetic Analysis
The collected sample is analysed in our state-of-the-art laboratory to identify genetic variations that influence drug metabolism and response. At AttoDiagnostics, we use Thermo Fisher or Illumina platforms with a panel of validated drug metabolising enzymes (DMEs) and protein transport markers that provide coverage for genetic response to the major cardiovascular medications.
Step 3
Comprehensive Report
You receive a detailed report outlining the implications of the genetic findings on medication selection and dosing. This report has a ‘quick view’ of the medication types covered, with their relative risks for the subject. A further optional in-depth report offers deeper insight into clinical recommendations and treatment decisions, covering potential drug-drug interaction for polypharmacy clients ensuring personalised and effective patient care.
